0

Close
 
Upcoming Allied Market Research
2023
Obsessive Compulsive Disorder (ocd) Drug Market

Obsessive Compulsive Disorder (OCD) Drug Market

by Therapy Type (Contamination Obessions, Checking Compulsions, Obessions Without Visible Complusions, Symmetery Obessions with Ordering Complusions, Hoarding), by Symptoms Type (Cognitive Behavioural Therapy, Augmentation Therapy, Aversion Therapy, Systematic Desensitization, Others) and by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13219
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Obsessive Compulsive Disorder (ocd) Drug Market

Request Now !

Obsessive Compulsive Disorder Drug Market Overview 2030

Obsessive compulsive disorder is a behavioral or mental disorder in which person has certain thoughts repeatedly or perform certain routines repeatedly. The person who is suffering from this disorder is unable to control his thoughts and activities in short period of time. Excessive hand washing, counting things, and checking to see if a door is locked are most common symptoms of obsessive compulsive disorder. This medical condition is associated with tics, anxiety disorder, and rise in risk of suicide. Selective serotonin reuptake inhibitors, antidepressants, antipsychotics, antianxiety, and others are prescribed to the patient for treatment of this disease. Moreover, clomipramine, aripiprazole, dextroamphetamine, risperidone, and olanzapine are the drugs which can be used in treatment of the obsessive compulsive disorder.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the obsessive compulsion disorder drug market.

Top Impacting Factors

  • Increase in incidence of stress and anxiety, rise in cases of infectious diseases across the globe, surge in number of people suffering from brain trauma, increase in demand for targeted drug therapies, and surge in awareness regarding early diagnosis of diseases are the major factors that drive the growth of market.
  • In addition, increase in adoption of advance healthcare devices, rise in development in obsessive compulsive disorder treatment procedures, surge in demand for off-level drugs & therapies, increase in R & D activities for launch of approved obsessive compulsive disorder treatment drugs, and surge in investment of healthcare sector are some factors that fuel the growth of market.
  • However, side effects related use of obsessive compulsive disorder drugs and generic versions of branded drugs restrain the growth of market.
  • Contrarily, increase in government support to spread awareness regarding treatment of obsessive compulsive disorder is expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2019, Lupin announced launch of antidepressant tablets in U.S. This tablet contain 10 mg / 20 mg Fluoxetine which can be used in treatment of obsessive compulsive disorder and bulimia nervosa.

In 2019, Lupin announced approval of U.S. Food and Drug Administration for launch of Anafranil capsules. This product contain Clomipramine which can be used in treatment of obsessive compulsive disorder.

In 2019, Upsher Smith launched generic version of Prozac Fluoxetine tablets in U.S. market. This drug help in treatment of obsessive compulsive disorder.

Key Benefits of the Report

  • This study presents the analytical depiction of obsessive compulsion disorder drug market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Obsessive Compulsion Disorder Drug Market Report             

  • Which are the leading players active in the obsessive compulsion disorder drug market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "obsessive compulsion disorder drug"?
  • What is "obsessive compulsion disorder drug" market prediction in the future?
  • Who are the leading global players in the "obsessive compulsion disorder drug" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "obsessive compulsion disorder drug" market report?

 Obsessive Compulsive Disorder (OCD) Drug Market Report Highlights

Aspects Details
By Therapy Type
  • Contamination Obessions
  • Checking Compulsions
  • Obessions Without Visible Complusions
  • Symmetery Obessions with Ordering Complusions
  • Hoarding
By Symptoms Type
  • Cognitive Behavioural Therapy
  • Augmentation Therapy
  • Aversion Therapy
  • Systematic Desensitization
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players F. Hoffmann-La Roche Ltd, Mylan N.V., Eli Lilly and Company, Abbott, Sanofi, Addex therapeutics, Zydus Cadila., Omeros Corporation, Brainsway, Meiji Holdings Co., Ltd, Novartis AG, Merck & Co., Inc., C4x discovery holdings plc., Sellas, Pfizer Inc., AbbVie Inc., AstraZeneca
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET, BY THERAPY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapy Type

    • 4.2. Contamination Obessions

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Checking Compulsions

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Obessions Without Visible Complusions

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Symmetery Obessions With Ordering Complusions

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Hoarding

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SYMPTOMS TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Symptoms Type

    • 5.2. Cognitive Behavioural Therapy

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Augmentation Therapy

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Aversion Therapy

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Systematic Desensitization

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Online Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Retail Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Therapy Type

      • 7.2.3. Market Size and Forecast, By Symptoms Type

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.2.6.1. Market Size and Forecast, By Therapy Type
        • 7.2.6.2. Market Size and Forecast, By Symptoms Type
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.2.7.1. Market Size and Forecast, By Therapy Type
        • 7.2.7.2. Market Size and Forecast, By Symptoms Type
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.2.8.1. Market Size and Forecast, By Therapy Type
        • 7.2.8.2. Market Size and Forecast, By Symptoms Type
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Therapy Type

      • 7.3.3. Market Size and Forecast, By Symptoms Type

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.3.6.1. Market Size and Forecast, By Therapy Type
        • 7.3.6.2. Market Size and Forecast, By Symptoms Type
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.3.7.1. Market Size and Forecast, By Therapy Type
        • 7.3.7.2. Market Size and Forecast, By Symptoms Type
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.3.8.1. Market Size and Forecast, By Therapy Type
        • 7.3.8.2. Market Size and Forecast, By Symptoms Type
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.3.9.1. Market Size and Forecast, By Therapy Type
        • 7.3.9.2. Market Size and Forecast, By Symptoms Type
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.3.10.1. Market Size and Forecast, By Therapy Type
        • 7.3.10.2. Market Size and Forecast, By Symptoms Type
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.3.11.1. Market Size and Forecast, By Therapy Type
        • 7.3.11.2. Market Size and Forecast, By Symptoms Type
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.3.12.1. Market Size and Forecast, By Therapy Type
        • 7.3.12.2. Market Size and Forecast, By Symptoms Type
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Therapy Type

      • 7.4.3. Market Size and Forecast, By Symptoms Type

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.6.1. Market Size and Forecast, By Therapy Type
        • 7.4.6.2. Market Size and Forecast, By Symptoms Type
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.7.1. Market Size and Forecast, By Therapy Type
        • 7.4.7.2. Market Size and Forecast, By Symptoms Type
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.8.1. Market Size and Forecast, By Therapy Type
        • 7.4.8.2. Market Size and Forecast, By Symptoms Type
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.9.1. Market Size and Forecast, By Therapy Type
        • 7.4.9.2. Market Size and Forecast, By Symptoms Type
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.10.1. Market Size and Forecast, By Therapy Type
        • 7.4.10.2. Market Size and Forecast, By Symptoms Type
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.11.1. Market Size and Forecast, By Therapy Type
        • 7.4.11.2. Market Size and Forecast, By Symptoms Type
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.12.1. Market Size and Forecast, By Therapy Type
        • 7.4.12.2. Market Size and Forecast, By Symptoms Type
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.13.1. Market Size and Forecast, By Therapy Type
        • 7.4.13.2. Market Size and Forecast, By Symptoms Type
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.4.14.1. Market Size and Forecast, By Therapy Type
        • 7.4.14.2. Market Size and Forecast, By Symptoms Type
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Therapy Type

      • 7.5.3. Market Size and Forecast, By Symptoms Type

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.5.6.1. Market Size and Forecast, By Therapy Type
        • 7.5.6.2. Market Size and Forecast, By Symptoms Type
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.5.7.1. Market Size and Forecast, By Therapy Type
        • 7.5.7.2. Market Size and Forecast, By Symptoms Type
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.5.8.1. Market Size and Forecast, By Therapy Type
        • 7.5.8.2. Market Size and Forecast, By Symptoms Type
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.5.9.1. Market Size and Forecast, By Therapy Type
        • 7.5.9.2. Market Size and Forecast, By Symptoms Type
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.5.10.1. Market Size and Forecast, By Therapy Type
        • 7.5.10.2. Market Size and Forecast, By Symptoms Type
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Obsessive Compulsive Disorder (ocd) Drug Market

        • 7.5.11.1. Market Size and Forecast, By Therapy Type
        • 7.5.11.2. Market Size and Forecast, By Symptoms Type
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Abbott

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Pfizer Inc.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Merck And Co., Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Sanofi

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Novartis AG

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. AbbVie Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Eli Lilly And Company

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. AstraZeneca

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Meiji Holdings Co., Ltd

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Brainsway

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Sellas

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

    • 9.12. Mylan N.V.

      • 9.12.1. Company Overview

      • 9.12.2. Key Executives

      • 9.12.3. Company Snapshot

      • 9.12.4. Operating Business Segments

      • 9.12.5. Product Portfolio

      • 9.12.6. Business Performance

      • 9.12.7. Key Strategic Moves and Developments

    • 9.13. Addex Therapeutics

      • 9.13.1. Company Overview

      • 9.13.2. Key Executives

      • 9.13.3. Company Snapshot

      • 9.13.4. Operating Business Segments

      • 9.13.5. Product Portfolio

      • 9.13.6. Business Performance

      • 9.13.7. Key Strategic Moves and Developments

    • 9.14. F. Hoffmann-La Roche Ltd

      • 9.14.1. Company Overview

      • 9.14.2. Key Executives

      • 9.14.3. Company Snapshot

      • 9.14.4. Operating Business Segments

      • 9.14.5. Product Portfolio

      • 9.14.6. Business Performance

      • 9.14.7. Key Strategic Moves and Developments

    • 9.15. Omeros Corporation

      • 9.15.1. Company Overview

      • 9.15.2. Key Executives

      • 9.15.3. Company Snapshot

      • 9.15.4. Operating Business Segments

      • 9.15.5. Product Portfolio

      • 9.15.6. Business Performance

      • 9.15.7. Key Strategic Moves and Developments

    • 9.16. C4x Discovery Holdings Plc.

      • 9.16.1. Company Overview

      • 9.16.2. Key Executives

      • 9.16.3. Company Snapshot

      • 9.16.4. Operating Business Segments

      • 9.16.5. Product Portfolio

      • 9.16.6. Business Performance

      • 9.16.7. Key Strategic Moves and Developments

    • 9.17. Zydus Cadila.

      • 9.17.1. Company Overview

      • 9.17.2. Key Executives

      • 9.17.3. Company Snapshot

      • 9.17.4. Operating Business Segments

      • 9.17.5. Product Portfolio

      • 9.17.6. Business Performance

      • 9.17.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR CONTAMINATION OBESSIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR CHECKING COMPULSIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR OBESSIONS WITHOUT VISIBLE COMPLUSIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR SYMMETERY OBESSIONS WITH ORDERING COMPLUSIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR HOARDING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR COGNITIVE BEHAVIOURAL THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR AUGMENTATION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR AVERSION THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR SYSTEMATIC DESENSITIZATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 22. U.S. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 23. U.S. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 24. U.S. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. CANADA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. CANADA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 27. CANADA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. GERMANY OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. ITALY OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 42. ITALY OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. UK OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. UK OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 49. UK OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. RUSSIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 52. RUSSIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. REST OF EUROPE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 55. REST OF EUROPE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. CHINA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 61. CHINA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 62. CHINA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. JAPAN OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 65. JAPAN OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. INDIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. INDIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 68. INDIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. AUSTRALIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 74. AUSTRALIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. THAILAND OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 77. THAILAND OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. MALAYSIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 80. MALAYSIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. INDONESIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 83. INDONESIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. REST OF ASIA PACIFIC OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. BRAZIL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 93. BRAZIL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. SAUDI ARABIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 99. SAUDI ARABIA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 100. UAE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 101. UAE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 102. UAE OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. ARGENTINA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 105. ARGENTINA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 106. REST OF LAMEA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY THERAPY TYPE, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY SYMPTOMS TYPE, 2022-2032 ($MILLION)
  • TABLE 108. REST OF LAMEA OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 109. ABBOTT: KEY EXECUTIVES
  • TABLE 110. ABBOTT: COMPANY SNAPSHOT
  • TABLE 111. ABBOTT: OPERATING SEGMENTS
  • TABLE 112. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 113. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. PFIZER INC.: KEY EXECUTIVES
  • TABLE 115. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 116. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 117. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 118. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 120. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 121. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 122. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 123. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124. SANOFI: KEY EXECUTIVES
  • TABLE 125. SANOFI: COMPANY SNAPSHOT
  • TABLE 126. SANOFI: OPERATING SEGMENTS
  • TABLE 127. SANOFI: PRODUCT PORTFOLIO
  • TABLE 128. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 129. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 130. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 131. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 132. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 133. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 134. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 135. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 136. ABBVIE INC.: OPERATING SEGMENTS
  • TABLE 137. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 138. ABBVIE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 139. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 140. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 141. ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 142. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 143. ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 144. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 145. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 146. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 147. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 148. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 149. MEIJI HOLDINGS CO., LTD: KEY EXECUTIVES
  • TABLE 150. MEIJI HOLDINGS CO., LTD: COMPANY SNAPSHOT
  • TABLE 151. MEIJI HOLDINGS CO., LTD: OPERATING SEGMENTS
  • TABLE 152. MEIJI HOLDINGS CO., LTD: PRODUCT PORTFOLIO
  • TABLE 153. MEIJI HOLDINGS CO., LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 154. BRAINSWAY: KEY EXECUTIVES
  • TABLE 155. BRAINSWAY: COMPANY SNAPSHOT
  • TABLE 156. BRAINSWAY: OPERATING SEGMENTS
  • TABLE 157. BRAINSWAY: PRODUCT PORTFOLIO
  • TABLE 158. BRAINSWAY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 159. SELLAS: KEY EXECUTIVES
  • TABLE 160. SELLAS: COMPANY SNAPSHOT
  • TABLE 161. SELLAS: OPERATING SEGMENTS
  • TABLE 162. SELLAS: PRODUCT PORTFOLIO
  • TABLE 163. SELLAS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 164. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 165. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 166. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 167. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 168. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 169. ADDEX THERAPEUTICS: KEY EXECUTIVES
  • TABLE 170. ADDEX THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 171. ADDEX THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 172. ADDEX THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 173. ADDEX THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 174. F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 175. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 176. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 177. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 178. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 179. OMEROS CORPORATION: KEY EXECUTIVES
  • TABLE 180. OMEROS CORPORATION: COMPANY SNAPSHOT
  • TABLE 181. OMEROS CORPORATION: OPERATING SEGMENTS
  • TABLE 182. OMEROS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 183. OMEROS CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 184. C4X DISCOVERY HOLDINGS PLC.: KEY EXECUTIVES
  • TABLE 185. C4X DISCOVERY HOLDINGS PLC.: COMPANY SNAPSHOT
  • TABLE 186. C4X DISCOVERY HOLDINGS PLC.: OPERATING SEGMENTS
  • TABLE 187. C4X DISCOVERY HOLDINGS PLC.: PRODUCT PORTFOLIO
  • TABLE 188. C4X DISCOVERY HOLDINGS PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 189. ZYDUS CADILA.: KEY EXECUTIVES
  • TABLE 190. ZYDUS CADILA.: COMPANY SNAPSHOT
  • TABLE 191. ZYDUS CADILA.: OPERATING SEGMENTS
  • TABLE 192. ZYDUS CADILA.: PRODUCT PORTFOLIO
  • TABLE 193. ZYDUS CADILA.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
  • FIGURE 2. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET
  • FIGURE 3. SEGMENTATION OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALOBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET
  • FIGURE 11. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION, BY BY THERAPY TYPE
  • FIGURE 12. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR CONTAMINATION OBESSIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR CHECKING COMPULSIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR OBESSIONS WITHOUT VISIBLE COMPLUSIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR SYMMETERY OBESSIONS WITH ORDERING COMPLUSIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR HOARDING, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION, BY BY SYMPTOMS TYPE
  • FIGURE 18. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR COGNITIVE BEHAVIOURAL THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR AUGMENTATION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR AVERSION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR SYSTEMATIC DESENSITIZATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 24. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 28. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 29. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 30. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 31. COMPETITIVE DASHBOARD
  • FIGURE 32. COMPETITIVE HEATMAP: OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG MARKET
  • FIGURE 33. Top player positioning, 2022
  • FIGURE 34. ABBOTT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. ABBOTT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. ABBOTT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. SANOFI: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. SANOFI: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. ABBVIE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. ABBVIE INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. ELI LILLY AND COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. MEIJI HOLDINGS CO., LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. MEIJI HOLDINGS CO., LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. MEIJI HOLDINGS CO., LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. BRAINSWAY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. BRAINSWAY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. BRAINSWAY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. SELLAS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. SELLAS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. SELLAS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 67. MYLAN N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 69. MYLAN N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 70. ADDEX THERAPEUTICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. ADDEX THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 72. ADDEX THERAPEUTICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 73. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 74. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 75. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 76. OMEROS CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 77. OMEROS CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 78. OMEROS CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 79. C4X DISCOVERY HOLDINGS PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 80. C4X DISCOVERY HOLDINGS PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 81. C4X DISCOVERY HOLDINGS PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 82. ZYDUS CADILA.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 83. ZYDUS CADILA.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 84. ZYDUS CADILA.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Obsessive Compulsive Disorder (ocd) Drug Market

Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers